End Stage Chronic Renal FailurePREFDOMNCT07535320
Study of Patient Preferences in Dialysis Treatment Choice: a Discrete Choice Experiment
An observational study of End Stage Chronic Renal Failure, run by University Hospital, Caen at 2 sites in France.
Trial summary
Background Compared to in-center dialysis, home dialysis is associated with better quality of life and lower healthcare system costs. However, barriers remain to its wider adoption. Chronic disease, particularly at an advanced stage, is a major driver of socioeconomic vulnerability. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- End Stage Chronic Renal Failure
- What is being tested?
- Questionnaire
- How many people
- 500 participants
- Where
- 2 sitesFrance
- Study dates
- 16 Dec 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with chronic kidney disease in the advanced stage
Who may be able to join
- Adult patient
- Patient with advanced chronic kidney disease receiving pre-surgery information (presentation of methods)
- Patient enrolled in a social security program
- Patient able to read and understand French
- Patient able to complete the questionnaire (cognitive and sensory)
Who cannot join
- Minor patients
- Patients transitioning from one method of extrarenal purification to another
- Patients requiring urgent dialysis
- Patients who cannot read or understand French
- Patients under legal protection (guardianship, curatorship, judicial protection)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France2 sites, 2 recruiting
- Recruiting
CHU de Caen
Caen, 14000
Sonia Guillouët, PhD, +33231568291, sonia.guillouet@unicaen.fr
Ludivine Videloup, RN
- Recruiting
CHU
Caen, 14000
SONIA GUILLOUET, DR, +33231563089, achourakram10@gmail.com
About this study
Background Compared to in-center dialysis, home dialysis is associated with better quality of life and lower healthcare system costs. However, barriers remain to its wider adoption. Chronic disease, particularly at an advanced stage, is a major driver of socioeconomic vulnerability. Among dialysis patients, the proportion of individuals covered by France's Universal Health Protection scheme (PUMA) is higher than in the general population. Similarly, those from the most disadvantaged social classes are overrepresented among dialysis patients compared to the overall French population. Dialysis can also lead to job loss. Financial compensation schemes may influence the choice of home dialysis. In France, patients who perform dialysis at home-either independently or with help from a trained family caregiver-are eligible for a "third-person compensatory allowance" (DTP). For some socioeconomically vulnerable patients, eligibility for DTP may influence their decision to opt for home treatment. The DTP is specific to the French healthcare system but could be considered in other countries, particularly within the European Union. Indeed, in most countries with income levels comparable to France, the additional cost of home dialysis is borne by the patient. This study aims to determine whether receiving financial compensation plays a role in choosing a dialysis modality (home-based versus in-center or assisted home dialysis).
Objectives To investigate factors associated with patient preferences regarding renal replacement therapy.
Read more
Methods A discrete choice experiment (DCE) was conducted comparing two options: home dialysis (PD and HHD, with DTP) versus in-center hemodialysis (no DTP).
Perspectives If financial compensation influences patients' choices toward home dialysis, the DTP model could be used to address barriers to home-based treatment.
- Conditions
- End Stage Chronic Renal Failure
- Being tested
- Questionnaire
- Keywords
- Nephrology, Home Dialysis, Chronic Kidney Disease, Discrete Choice Experiment
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Patients are given a questionnaire. The first part concerns sociodemographic characteristics. The second part concerns the choice of replacement therapy itself.
Patients must choose between three possible treatments: "If you had to choose a treatment based on the options provided, which one would you choose? Patients make this choice 13 times (the options change).
| Study group | Role | What they receive |
|---|---|---|
| Choice of dialysis | Patients with an end-stage renal disease who need to make a choice concerning their prefered dialysis' modality Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Preference coefficients for renal replacement therapy attributes, including monthly financial allowance, estimated using a discrete choice experiment
Participants will complete 13 discrete choice tasks, each requiring selection of one preferred scenario among three renal replacement therapy options. Scenarios are defined by combinations of five attributes: schedule flexibility, nurse availability, dialysis frequency, timing of sessions, and monthly financial allowance.
Preferences will be analyzed within a random utility framework using a mixed logit model. The primary outcome is the estimation of marginal utilities (preference coefficients) associated with each attribute level. Particular focus will be placed on the coefficient associated with the monthly financial allowance attribute, to assess its influence on the probability of choosing a home-based treatment modality.
This approach allows indirect elicitation of patient preferences without explicit ranking, consistent with economic theory of revealed preferences.
Measured: Baseline (during the single discrete choice experiment assessment at study enrollment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start16 Dec 2025
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End Stage Chronic Renal FailureStudies of the same condition, open and under way.
- More trials run by University Hospital, CaenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Caen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07535320
- Sponsor's protocol ID
- 24-0172
- Acronym
- PREFDOM
- Status last verified
- Dec 2025
- First submitted
- 25 Aug 2025
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Patient Preferences in Dialysis Treatment Choice: a Discrete Choice Experiment
- ClinicalTrials.gov ID
- NCT07535320
- Acronym / sponsor ID
- PREFDOM / 24-0172
- Conditions
- End Stage Chronic Renal Failure
- Keywords
- Nephrology, Home Dialysis, Chronic Kidney Disease, Discrete Choice Experiment
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University Hospital, CaenUniversity, hospital or other
- Study start
- 16 Dec 2025 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Compared to in-center dialysis, home dialysis is associated with better quality of life and lower healthcare system costs. However, barriers remain to its wider adoption. Chronic disease, particularly at an advanced stage, is a major driver of socioeconomic vulnerability. Among dialysis patients, the proportion of individuals covered by France's Universal Health Protection scheme (PUMA) is higher than in the general population. Similarly, those from the most disadvantaged social classes are overrepresented among dialysis patients compared to the overall French population. Dialysis can also lead to job loss. Financial compensation schemes may influence the choice of home dialysis. In France, patients who perform dialysis at home-either independently or with help from a trained family caregiver-are eligible for a "third-person compensatory allowance" (DTP). For some socioeconomically vulnerable patients, eligibility for DTP may influence their decision to opt for home treatment. The DTP is specific to the French healthcare system but could be considered in other countries, particularly within the European Union. Indeed, in most countries with income levels comparable to France, the additional cost of home dialysis is borne by the patient. This study aims to determine whether receiving financial compensation plays a role in choosing a dialysis modality (home-based versus in-center or assisted home dialysis).
Objectives To investigate factors associated with patient preferences regarding renal replacement therapy.
Methods A discrete choice experiment (DCE) was conducted comparing two options: home dialysis (PD and HHD, with DTP) versus in-center hemodialysis (no DTP).
Perspectives If financial compensation influences patients' choices toward home dialysis, the DTP model could be used to address barriers to home-based treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Choice of dialysis | – | Other: QuestionnairePatients with an end-stage renal disease who need to make a choice concerning their prefered dialysis' modality |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic kidney disease in the advanced stage
Key inclusion criteria (5 listed)
- Adult patient
- Patient with advanced chronic kidney disease receiving pre-surgery information (presentation of methods)
- Patient enrolled in a social security program
- Patient able to read and understand French
- Patient able to complete the questionnaire (cognitive and sensory)
Key exclusion criteria (5 listed)
- Minor patients
- Patients transitioning from one method of extrarenal purification to another
- Patients requiring urgent dialysis
- Patients who cannot read or understand French
- Patients under legal protection (guardianship, curatorship, judicial protection)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnairePatients are given a questionnaire. The first part concerns sociodemographic characteristics. The second part concerns the choice of replacement therapy itself. Patients must choose between three possible treatments: "If you had to choose a treatment based on the options provided, which one would you choose? Patients make this choice 13 times (the options change). | Other | Choice of dialysis |
Primary outcome
Preference coefficients for renal replacement therapy attributes, including monthly financial allowance, estimated using a discrete choice experiment
Time frame: Baseline (during the single discrete choice experiment assessment at study enrollment)
Participants will complete 13 discrete choice tasks, each requiring selection of one preferred scenario among three renal replacement therapy options. Scenarios are defined by combinations of five attributes: schedule flexibility, nurse availability, dialysis frequency, timing of sessions, and monthly financial allowance. Preferences will be analyzed within a random utility framework using a mixed logit model. The primary outcome is the estimation of marginal utilities (preference coefficients) associated with each attribute level. Particular focus will be placed on the coefficient associated with the monthly financial allowance attribute, to assess its influence on the probability of choosing a home-based treatment modality. This approach allows indirect elicitation of patient preferences without explicit ranking, consistent with economic theory of revealed preferences.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for End Stage Chronic Renal Failure
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of End Stage Chronic Renal Failure, run by University Hospital, Caen at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clémence Tomadesso, Mrs (+33231063106, tomadesso-c@chu-caen.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Preference coefficients for renal replacement therapy attributes, including monthly financial allowance, estimated using a discrete choice experiment (time frame: Baseline (during the single discrete choice experiment assessment at study enrollment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.